RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Commentary on Twitter

The PRINCIPLE trial publishes its first peer reviewed paper, showing results from the study of azithromycin as a treatment for Covid-19 in the community. @TheLancet #UrgentCovidResearch #PRINCIPLETrial
?https://t.co/qKRI5PVpQk pic.twitter.com/BVQztDSvSC

— OxPrimaryCareSci (@OxPrimaryCare) March 5, 2021